Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40W1C | ISIN: US2936025046 | Ticker-Symbol:
NASDAQ
02.04.25
19:28 Uhr
2,670 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENSYSCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ENSYSCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ENSYSCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoEnsysce Biosciences, Inc. - 8-K, Current Report2
MoEnsysce Biosciences raises $1.1 million in stock sale2
MoEnsysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules117SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
18.03.Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain145~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce...
► Artikel lesen
10.03.Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results251Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPARGroundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire /...
► Artikel lesen
10.03.Ensysce Biosciences, Inc. - 10-K, Annual Report2
ENSYSCE BIOSCIENCES Aktie jetzt für 0€ handeln
10.03.Ensysce Biosciences, Inc. - 8-K, Current Report3
05.03.Ensysce Biosciences to Participate in the 37th Annual ROTH Conference191SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
05.02.Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment198~ Positive Enrollment Progress and Safety Data ~~ FDA Attention Establishes Momentum in the Pain Treatment Space ~ SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)...
► Artikel lesen
04.02.Ensysce Biosciences, Inc. - 8-K, Current Report-
22.01.Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR227~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...
► Artikel lesen
08.01.Ensysce Biosciences Inc.: Ensysce Biosciences Issues Annual Shareholder Letter246~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence...
► Artikel lesen
23.12.24Ensysce Biosciences regains compliance from Nasdaq5
23.12.24Ensysce Biosciences Inc.: Ensysce Biosciences Regains Full Compliance with Nasdaq850SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for...
► Artikel lesen
10.12.24Ensysce Biosciences Inc.: Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product224~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company...
► Artikel lesen
04.12.24Ensysce Biosciences Inc.: Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR208~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~ SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or...
► Artikel lesen
03.12.24Ensysce Biosciences Inc.: Ensysce Biosciences Announces 1-for-15 Reverse Stock Split391SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...
► Artikel lesen
03.12.24Ensysce Biosciences, Inc. - 8-K, Current Report1
26.11.24Ensysce Biosciences Inc.: Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial352~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...
► Artikel lesen
21.11.24Ensysce Biosciences, Inc. - 8-K, Current Report-
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1